clinical trial · NCT05321147
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Innate Pharma·phase1·completed·n = 20
Peripheral T Cell Lymphomalacutamab
brief summary
This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.
started
Mar 17, 2022
primary completion
Nov 19, 2023
completion
Feb 8, 2024
last updated
Mar 28, 2024
detailed description
This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive fixed dose of 750mg Lacutamab as a 1-hour IV infusion.
official title
A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol